LEXX (Lexaria Bioscience) Other Long-Term Liabilities: $-0.00 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LEXX Lexaria Bioscience Corp LEXX
38 GF Score
Price $14.15
GF Value $5.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lexaria Bioscience Other Long-Term Liabilities?

Lexaria Bioscience LEXX +14.85% 38 Other Long-Term Liabilities is $-0.00 Mil as of May. 2026. GuruFocus rates LEXX with a GF Score™ of 38/100 and a GF Value™ of $5.37 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Lexaria Bioscience's other long-term liabilities for the quarter that ended in May. 2026 was $-0.00 Mil.

Lexaria Bioscience's quarterly other long-term liabilities increased from Nov. 2025 ($-0.00 Mil) to Feb. 2026 ($0.00 Mil) but then declined from Feb. 2026 ($0.00 Mil) to May. 2026 ($-0.00 Mil).

Lexaria Bioscience's annual other long-term liabilities increased from Aug. 2023 ($0.00 Mil) to Aug. 2024 ($0.00 Mil) but then declined from Aug. 2024 ($0.00 Mil) to Aug. 2025 ($-0.00 Mil).

Lexaria Bioscience Other Long-Term Liabilities Related Terms

Lexaria Bioscience Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Lexaria Bioscience's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexaria Bioscience Other Long-Term Liabilities Chart

Lexaria Bioscience Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00

Lexaria Bioscience Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 0.00 -0.00
LEXX
38GF Score
Lexaria Bioscience Corp LEXX
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexaria Bioscience Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $-0.00 Mil mean?
Lexaria Bioscience (LEXX) has a Other Long-Term Liabilities of $-0.00 Mil as of May. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Lexaria Bioscience and its competitors.
Is Lexaria Bioscience's Other Long-Term Liabilities too high?
Lexaria Bioscience's current Other Long-Term Liabilities is $-0.00 Mil. Overall, Lexaria Bioscience has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Other Long-Term Liabilities compare to TPST and LPCN?
Lexaria Bioscience's Other Long-Term Liabilities of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Lexaria Bioscience and its competitors. Lexaria Bioscience's current Other Long-Term Liabilities is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.37, compared to a current price of $14.15 — trading 163.5% above its estimated fair value. The current Other Long-Term Liabilities is $-0.00 Mil. Lexaria Bioscience's overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Other Long-Term Liabilities is $-0.00 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexaria Bioscience (LEXX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued. The current stock price of $14.15 is trading 163.5% above its estimated GF Value™ of $5.37. GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.

Key valuation signals for LEXX:

  • Other Long-Term Liabilities: $-0.00 Mil
  • GF Value™: $5.37 vs. price of $14.15 (163.5% above fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexaria Bioscience Business Description

Address 740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
38GF Score

Get the complete analysis for LEXX

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.15
Price
$5.37
GF Value